JP2006511482A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511482A5
JP2006511482A5 JP2004542034A JP2004542034A JP2006511482A5 JP 2006511482 A5 JP2006511482 A5 JP 2006511482A5 JP 2004542034 A JP2004542034 A JP 2004542034A JP 2004542034 A JP2004542034 A JP 2004542034A JP 2006511482 A5 JP2006511482 A5 JP 2006511482A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
penten
isopropoxy
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004542034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511482A (ja
Filing date
Publication date
Priority claimed from US10/263,083 external-priority patent/US6979695B2/en
Application filed filed Critical
Publication of JP2006511482A publication Critical patent/JP2006511482A/ja
Publication of JP2006511482A5 publication Critical patent/JP2006511482A5/ja
Pending legal-status Critical Current

Links

JP2004542034A 2002-10-02 2003-10-01 コリン作動性受容体を活性化できる化合物 Pending JP2006511482A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/263,083 US6979695B2 (en) 1996-04-23 2002-10-02 Compounds capable of activating cholinergic receptors
PCT/US2003/031188 WO2004031151A1 (en) 2002-10-02 2003-10-01 Compounds capable of activating cholinergic receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011051171A Division JP2011144192A (ja) 2002-10-02 2011-03-09 コリン作動性受容体を活性化できる化合物

Publications (2)

Publication Number Publication Date
JP2006511482A JP2006511482A (ja) 2006-04-06
JP2006511482A5 true JP2006511482A5 (enExample) 2009-10-22

Family

ID=32068267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004542034A Pending JP2006511482A (ja) 2002-10-02 2003-10-01 コリン作動性受容体を活性化できる化合物
JP2011051171A Pending JP2011144192A (ja) 2002-10-02 2011-03-09 コリン作動性受容体を活性化できる化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011051171A Pending JP2011144192A (ja) 2002-10-02 2011-03-09 コリン作動性受容体を活性化できる化合物

Country Status (6)

Country Link
US (4) US6979695B2 (enExample)
EP (2) EP1556352A1 (enExample)
JP (2) JP2006511482A (enExample)
AU (1) AU2003282908B2 (enExample)
CA (1) CA2501335C (enExample)
WO (1) WO2004031151A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US7790757B2 (en) * 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
ATE442822T1 (de) * 2004-04-02 2009-10-15 Arterial Remodelling Technolog Stentanordnung auf polymerbasis
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
WO2007027729A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
ATE548363T1 (de) 2005-08-29 2012-03-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
ES2361338T3 (es) 2005-08-29 2011-06-16 Vertex Pharmaceuticals Incorporated Pirid-2-onas 3,5-disustituidas útiles como inhibidores de la familia tec de tirosina quinasas no ligadas a receptor.
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型
EP2357174A1 (en) 2006-05-09 2011-08-17 AstraZeneca AB Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
US20100028447A1 (en) 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
CN101772343A (zh) * 2007-07-31 2010-07-07 塔格赛普有限公司 (2s)-(4e)-n-甲基-5-(3-(5-异丙氧基吡啶)基)-4-戊烯-2-胺的经皮给药
WO2009018367A2 (en) * 2007-07-31 2009-02-05 Targacept, Inc. Novel salt forms of (2s)-(4e)-n-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine
US9463190B2 (en) 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8703802B2 (en) * 2010-05-20 2014-04-22 Targacept, Inc. Process for the preparation of aryl substituted olefinic amines
US9488490B2 (en) 2014-04-02 2016-11-08 Here Global B.V. Storing and accessing traffic data images in a limited bandwidth environment

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927838A (en) 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
DE4102289A1 (de) 1991-01-26 1992-07-30 Bayer Ag Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5242935A (en) 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5824692A (en) 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
AU4610896A (en) * 1995-01-06 1996-07-24 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5731314A (en) 1995-01-06 1998-03-24 Bencherif; Merouane Pharamceutical compositions for prevention and treatment of tourette's syndrome
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
AU5383196A (en) 1995-05-17 1996-11-29 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
DE69739142D1 (de) * 1996-04-23 2009-01-15 Targacept Inc Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6166048A (en) * 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
CA2281564A1 (en) * 1997-02-21 1998-08-27 R.J. Reynolds Tobacco Company Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6531606B1 (en) * 1997-02-21 2003-03-11 Targacept, Inc. Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US20050131034A1 (en) * 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
EP1086082B9 (en) * 1998-06-16 2005-03-02 Targacept, Inc. Arylsubstituted olefinic amines and their use as cholinergic receptors agonists
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6337351B1 (en) * 1998-10-22 2002-01-08 Targacept, Inc. Pharmaceutical compositions and methods for use
US6262124B1 (en) 1998-10-22 2001-07-17 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6455554B1 (en) * 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
EP1185514A1 (en) * 1999-06-07 2002-03-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6432954B1 (en) * 2000-07-14 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6743812B1 (en) * 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use

Similar Documents

Publication Publication Date Title
JP2006511482A5 (enExample)
RU2336267C2 (ru) Производные пирролидона в качестве ингибиторов маов
JP2007510619A5 (enExample)
JP2005511482A5 (enExample)
CA2155952A1 (en) Novel process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
EP2308828A3 (en) CaSR antagonist
MX2007007105A (es) Procedimiento para la preparacion de un derivado de 2-piridiletilcarboxamida.
CO5720995A2 (es) Compuesto novedoso
ATE183176T1 (de) Verfahren und zwischenprodukte zur herstellung von alpha-methoxyiminocarbonsäuremethylamiden
JP2007523874A5 (enExample)
ZA9810320B (en) Process for the preparation of 1,4-dihydropyridines and novel compounds of use for such purpose.
BRPI0510278A (pt) método para produzir compostos, produto, e, composto
JP2005526149A5 (enExample)
FI960184A0 (fi) Menetelmä HIV-proteaasi-inhibiittoreiden valmistamiseksi
JP2002501094A5 (enExample)
JP2003261506A5 (enExample)
RU2002118101A (ru) Способ получения {2-[4-(α-фенил-п-хлорбензил)пиперазин-1-ил]-этокси}-уксусной кислоты и новые промежуточные соединения
KR840002831A (ko) 피리미딘 유도체의 제조방법
RU2003127120A (ru) Пирролкарбоксамиды для применения в качестве фунгицидов
JP2004018389A5 (enExample)
RU95117103A (ru) Производные хинолинкарбоновой кислоты и способы их получения
EA200400642A1 (ru) Процесс получения этиловых эфиров 4-(8-хлор-5,6-дигидро-11h-бензо-(5,6)-циклогепта-(1,2b) пиридин-11-илиден)-1-пиперидинкарбоновой кислоты (лоратадина)
EP0812842A3 (en) Process for the preparation of 5-(alkoxymethyl)-2,3-pyridine-dicarboximide compounds
JPH10152487A5 (enExample)
JP2003513004A5 (enExample)